Cardiomyopathy in Danon disease

Article written and reviewed by Dr Luca Moretti

Danon disease is an X-linked vacuolar cardioskeletal myopathy caused by loss-of-function variants in LAMP2. The LAMP-2 protein is part of the lysosomal membrane and autophagic flux; when it is absent, autophagosomes and lysosomes do not properly complete cellular turnover and vacuoles, glycogen and undegraded material accumulate. The heart, which is subject to continuous energetic turnover, develops a cardiomyopathy with extremely high penetrance. The autophagic defect distinguishes Danon disease from sarcomeric cardiomyopathies and Pompe disease.

In males, onset often occurs in childhood or adolescence with extreme hypertrophy, pre-excitation, weakness and cognitive difficulties; progression to heart failure, arrhythmias, mechanical support or transplantation may be rapid. In females, the average presentation is later and sometimes exclusively cardiac, but it is not benign: hypertrophic and dilated phenotypes, arrhythmias and end-stage failure are possible. The sex difference mainly concerns age and multisystem involvement, not the absence of risk in women.

Rarity has favored diagnostic delays and the inappropriate label of hypertrophic cardiomyopathy with Wolff-Parkinson-White. Yet the association of young age, exceptionally thick walls, very broad high-voltage QRS complexes, pre-excitation, elevated CK or transaminases and neuromuscular signs is strongly suggestive. Early recognition of the Danon constellation allows family surveillance and discussion of advanced therapies before the hemodynamic window closes.

LAMP-2, autophagy and pathology

The LAMP2 gene produces isoforms through alternative splicing; LAMP-2B is particularly relevant in the heart and muscle. Loss of the protein impairs autophagosome-lysosome fusion and degradation of material, generating membrane-bound vacuoles and intracellular accumulation. This is not simple passive deposition: the entire quality-control system for proteins and organelles is altered. Turnover failure explains cell growth, dysfunction and progressive death.

Muscle biopsy shows vacuolar myopathy and may document absent or reduced LAMP-2 by immunohistochemistry. Glycogen is present, which is why the disease has been called glycogen storage disease IIb, but this designation may confuse it with Pompe disease and does not adequately describe autophagy. In the heart, disorganization, vacuoles and fibrosis become mechanical and electrical substrates. The pathological signature is useful in uncertain cases, not a requirement when genetics and phenotype are conclusive.

Most pathogenic variants disrupt the protein through nonsense, frameshift, splicing or large rearrangements. Missense variants require more cautious assessment because loss of function is the central mechanism and not every rare substitution is causal. In females, mosaicism from X inactivation distributes cardiomyocytes with and without protein, contributing to heterogeneity and fibrosis. Variant validation must therefore integrate molecular type, expression and segregation.

Male and female hearts

In hemizygous males, hypertrophy is often concentric and massive, with a small cavity initially and rapid progression toward dysfunction. Preserved ejection fraction does not represent stability when wall thickness, LGE and symptoms increase; output may be reduced despite an apparently normal percentage. Dilated atria, right ventricular dysfunction and functional regurgitation emerge with heart failure. Accelerated progression requires close serial measurements, not follow-up modeled on stable HCM.

In females, hypertrophy may be moderate or severe and coexist with fibrosis; some progress toward dilation and severe systolic reduction. Because weakness and cognitive difficulties may be absent, the disease is mistaken for sarcomeric HCM or idiopathic DCM. A pedigree with males who died or underwent transplantation young is a clue, but de novo mutations and small families are possible. The isolated female phenotype deserves the same genetic rigor.

Heart failure is the main prognostic determinant. Symptoms may accelerate over months, and high filling pressures, hyponatremia, worsening renal function and arrhythmias signal reduced reserve. Late referral to a transplant center may encounter pulmonary hypertension, cachexia or organ damage that increase risk. The transplant window should be discussed when the trajectory becomes concerning, not only after shock or inotropes.

Pre-excitation and arrhythmias

The ECG often shows striking voltages, broad QRS complexes, repolarization abnormalities and pre-excitation patterns. Not all are due to a classic atrioventricular accessory pathway: fasciculoventricular connections have been documented, which pre-excite the ventricle but do not sustain atrioventricular tachycardia and should not be ablated. Myocardial architecture may also contribute to abnormal activation. Electrophysiologic diagnosis precedes any procedure.

Supraventricular tachycardias, atrial fibrillation and ventricular arrhythmias coexist with structural progression. Ablating a pathway responsible for tachycardia eliminates that circuit but does not alter LAMP2, fibrosis or heart-failure risk. Holter monitoring, implantable devices and electrophysiologic study are selected according to symptoms and findings. Noncausal pre-excitation should not be mistaken for a complete explanation of the cardiomyopathy.

An ICD is indicated after cardiac arrest or appropriate sustained tachycardia and is considered for primary prevention based on syncope, arrhythmias, fibrosis, dysfunction and family history. Shocks do not treat low output or electromechanical dissociation, and extreme hypertrophy may make implantation and defibrillation technically complex. Shock protection must be coordinated with the support and transplant plan, avoiding a device that delays definitive therapy.

Extracardiac manifestations

Skeletal myopathy is generally proximal and more evident in males; CK, AST, ALT and LDH may be elevated from muscle origin. Interpreting transaminases as isolated liver disease can generate misleading investigations. Weakness is often less disabling than heart disease at a young age but becomes important in rehabilitation, anesthesia and after transplantation. Neuromuscular reserve should be measured before major procedures.

Cognitive difficulties are variable and may involve learning, attention and executive functions more than uniform disability. Neuropsychological assessment and school support improve the ability to understand therapies and adhere to follow-up. Pigmentary retinopathy and visual abnormalities require ophthalmologic examination even though they are not always symptomatic. Functional support is part of care rather than an accessory to cardiology.

Hepatic involvement is often biochemical; other manifestations have been reported, but the profile remains dominated by heart, muscle, cognition and retina. In females, limited extracardiac expression does not reduce suspicion when cardiomyopathy and pedigree are compatible. Differential penetrance explains why the same clinical criteria have different sensitivity in the two sexes.

Imaging, laboratory tests and differential diagnosis

Echocardiography documents wall thickness, gradients, function, atria and rate of progression. Obstruction may occur but is not the dominant feature; progressive reduction in strain or ejection fraction has greater prognostic value. CMR quantifies mass and scar, often extensive, with a nonischemic distribution. Fibrotic burden helps explain arrhythmias and reduced reserve, although without an exclusive pattern.

CK and transaminases, ECG and history guide testing, but confirmation is genetic. Fabry disease is distinguished through alpha-galactosidase, lyso-Gb3 and often low T1; Pompe through GAA activity and the infantile cardiorespiratory phenotype; PRKAG2 has pre-excitation and conduction disease but generally not the muscle-cognition triad; sarcomeric HCM does not explain the whole picture. A mechanistic differential diagnosis selects targeted analyses while avoiding unnecessary biopsy.

LAMP2 testing should include sequencing and, when necessary, deletion or duplication analysis. A concordant pathogenic variant confirms the diagnosis; a VUS requires segregation, RNA or protein studies and cannot guide predictive testing. LAMP-2 immunohistochemistry and muscle or cardiac biopsy are useful when genetics is negative or ambiguous despite a strong phenotype. Complete molecular evidence avoids both technical false negatives and causality assigned to benign variants.

Cardiology treatment and advanced therapies

There is no approved pharmacologic therapy that restores LAMP-2. Heart failure with reduced ejection fraction is treated according to guidelines, but hypotension, an initially small cavity and rapid progression may limit titration. Diuretics control congestion; arrhythmias and thromboembolism are managed according to indication. Conventional therapy reduces complications but should not create the illusion that the autophagic defect has been halted.

Heart transplantation is the survival-modifying therapy in the terminal phase, and available series show acceptable outcomes in selected candidates. Assessment includes muscle function, cognition, rehabilitation capacity, retina and family support; mild myopathy is not by itself a contraindication. After transplantation, the disease does not recur in the donor heart through cellular transmission, but extracardiac manifestations may progress. Early selection maximizes benefit and allows a shared pathway.

Ventricular assist support can be a bridge, but a small cavity, hypertrophy, right ventricular dysfunction and body size make implantation complex, especially in young patients. Prolonged inotropes increase risks and should not become the first contact with the advanced center. Cardiopulmonary testing, hemodynamics, biomarkers and serial hospitalizations describe the trajectory better than a single ejection fraction. Longitudinal assessment identifies the point at which the risk of waiting exceeds that of transplantation.

Functional assessment and heart-failure risk

Ejection fraction loses sensitivity during the hypertrophic phase because a small cavity may eject a normal percentage with reduced stroke volume. Strain, stroke volume, atria, pulmonary pressure, right ventricular function and exercise capacity better describe reserve. Natriuretic peptides and troponin are interpreted serially. Occult low output should be recognized before creatinine, hyponatremia and congestion make titration or transfer impossible.

Cardiopulmonary exercise testing can document reduced oxygen consumption and blood-pressure response, but weakness and comprehension modify performance. In children, appropriate protocols and predicted values are used; an intraindividual decline is more meaningful than a single percentile. Integrated function combines heart and muscle and becomes particularly useful when deciding when to begin transplant evaluation.

Right-heart catheterization measures output, pressures and resistance when noninvasive data are insufficient or before transplantation. Pulmonary hypertension from left heart disease can become an obstacle if referral is late; pulmonary vasodilators should not be prescribed automatically. The hemodynamic window is preserved by controlling congestion and anticipating evaluation, not by chasing an isolated pressure.

Drugs, procedures and anesthesia

Beta-blockers may reduce tachycardia and obstruction, but bradycardia and low output limit their use; ACE inhibitors, ARBs, mineralocorticoid antagonists and SGLT2 inhibitors are considered in the dysfunctional phenotype with the same attention to blood pressure, kidney function and age. Danon-specific evidence is absent. Physiologic titration uses heart-failure goals without pretending that a target dose derived from common DCM is always achievable.

Significant obstruction should be confirmed at rest and with provocation. Surgical or alcohol septal reduction does not correct the disease and may add block or scar; it is discussed only when the gradient dominates symptoms and the advanced-therapy strategy is clear. A proportionate procedure avoids an anatomical intervention in a heart destined to progress rapidly because of a diffuse mechanism.

Anesthesia requires assessment of obstruction, function, arrhythmias, devices and respiratory weakness. Fasting, hypovolemia and vasodilation can reduce output; drugs that prolong QT or depress the myocardium are chosen cautiously. An experienced pediatric or adult center plans monitoring and access to mechanical support. Perioperative safety depends more on hemodynamic preparation than on a generic list of forbidden anesthetics.

Diagnosis in relatives and women

A woman with apparently isolated HCM may be the first recognized case. The absence of elevated CK, cognitive difficulties or pre-excitation does not exclude Danon disease, and LGE distribution may suggest a nonsarcomeric phenotype without being diagnostic. A panel should include LAMP2 and copy-number analysis. Diagnosis in females requires particular attention to splicing variants and deletions that point sequencing alone may miss.

In children who are positive but without hypertrophy, a baseline is established with ECG, imaging and laboratory tests, avoiding unevaluated intense sport but also absolute restrictions in the absence of phenotype. Frequency increases during puberty or if abnormalities appear. A new short PR, rapid increase in voltage or wall thickness changes strategy. Presymptomatic surveillance aims to detect a trajectory rather than produce a permanent certificate of stable disease.

A de novo variant does not eliminate parental testing because germline or somatic mosaicism has reproductive implications and a mildly affected parent may have been overlooked. In deceased relatives, records, images and stored samples can clarify segregation. Family reconstruction improves classification and identifies who needs a transplant pathway before symptoms.

Gene therapy and research

Replacement of LAMP2B using viral vectors is a biologically plausible strategy and has reached clinical investigation. Safety, dose, immune response, cardiac distribution and durability must still be demonstrated; early signals do not equal established efficacy. Inclusion criteria and management belong to approved protocols. Experimental gene therapy should be presented with proportionate hope and without delaying indicated transplantation or devices.

Biomarkers of autophagic flux, quantitative imaging and international registries seek to measure response and natural history. Rarity, female heterogeneity and use of transplantation make traditional endpoints difficult. Controlled studies and long-term follow-up remain essential even when therapeutic need is enormous. Evidence discipline protects patients from premature inference and makes each new platform interpretable.

Antibody production against the capsid or new protein, inability to redose and hepatic risk are specific problems of viral platforms. An initial biomarker response does not prove that all cardiomyocytes received a durable dose, and body growth may dilute the effect in a child. Therapeutic durability requires years of observation, including arrhythmias, transplantation, muscle and quality of life.

Cellular models derived from iPSCs allow study of autophagy and drugs but imperfectly reproduce the mature loaded heart. Registries with raw ECG, CMR and genetic data can define endpoints and external controls if bias is reduced. Translational research is stronger when a laboratory measurement is linked to the clinical trajectory rather than only to a histologic snapshot.

Participation in a study does not automatically suspend standard therapy or guarantee future access to the product. Consent, the possibility of placebo or an ineffective dose, prolonged follow-up and event management must be understood by the patient and family. The experimental choice remains compatible with parallel transplant evaluation, preventing an uncertain option from consuming a definitive window.

Family follow-up and prognosis

Cardiac monitoring is close and includes ECG, echocardiography, rhythm, CMR, biomarkers and functional capacity, with shorter intervals during increasing hypertrophy or early signs of dysfunction. Neurology, rehabilitation, ophthalmology, psychology and genetics follow the other domains. Fever, anesthesia and procedures require attention to cardiac and muscle function. The multidisciplinary network should have one center responsible for the overall trajectory.

Cascade screening uses the familial variant. An affected man transmits the variant to all daughters and no sons; a heterozygous woman has a 50% chance of transmitting it to each son or daughter. Positive relatives receive cardiac assessment even if asymptomatic because preventing delays is the main available intervention. Presymptomatic diagnosis does not eliminate uncertainty but creates proportionate surveillance.

Prognosis remains serious: in males, terminal events often cluster by young adulthood, whereas in females they occur later but with substantial morbidity. Historical averages do not predict the individual and are modified by diagnosis, devices and transplantation. Correct communication combines the urgency of planning with the concrete possibility of good survival after transplantation. Operational prognosis serves to make decisions in time, not to set an expiry date.

School and work require a plan for medications, devices, symptoms and emergency access, but activity is adapted to abilities rather than prohibited because of the diagnosis. Fatigue may derive from the heart, muscle, sleep or therapy and should be broken down. Protected participation maintains autonomy and provides functional information that a resting visit does not measure.

Exercise is not prescribed using a single protocol. Extreme hypertrophy, obstruction, arrhythmias or heart failure limit intensity and competitive sport, whereas supervised light activity may preserve muscle and well-being. Exercise testing and device data help define the response. The dynamic prescription is updated with rapid evolution and does not remain valid for years without review.

Contraception considers heart failure, thrombosis, drugs and interactions; pregnancy in a woman with Danon disease requires assessment of function, arrhythmias, devices and reserve before conception. Volume expansion and the postpartum period may precipitate failure. Cardio-obstetric planning distinguishes maternal risk from the 50% probability of transmitting the variant.

In pediatric transplantation, body size, antibodies, waiting time and school support add complexity. Cognitive difficulties require appropriate consent and adherence tools, not automatic exclusion; the family network is assessed and supported. Transplant equity judges individual capacity and prognosis rather than using a multisystem diagnosis as a shortcut.

After transplantation, immunosuppression, corticosteroids and inactivity may accentuate weakness, making a neuromuscular baseline essential. Rehabilitation, nutrition and infection monitoring are individualized. Graft function may be excellent while myopathy evolves slowly. Post-transplant care keeps the neurologist on the team and does not transfer all follow-up to transplant cardiology alone.

Psychological support addresses the experience of young family deaths, uncertainty and the prospect of transplantation. Overly deterministic information can cause resignation, whereas minimizing progression hinders timely decisions. Calibrated communication uses data by sex and stage, states cohort limitations and defines concrete actions that preserve control.

Each visit should end with warning thresholds: syncope, persistent tachycardia, rapid weight gain, orthopnea, reduced activity or device shocks require earlier contact. The patient should not interpret the change alone. The escalation network reduces the interval between deterioration and advanced reassessment, an especially valuable interval in Danon progression.

End-of-life decisions should be addressed when transplantation is not possible or support does not meet goals, without waiting for a resuscitation event. Deactivation of shock therapies, dyspnea control and family support can coexist with diuretics and other active care. Advance planning protects wishes and dignity in a disease in which deterioration can be sudden.

Pediatric and adult data are not automatically interchangeable. Wall thickness, capacity, devices and doses depend on growth, while in adult women comorbidities and pregnancy modify risk. Stage-specific expertise allows biological knowledge to be transferred without applying thresholds developed at a different age and maintains continuity among congenital, pediatric and adult cardiology.

A correct diagnosis also avoids treatments intended for sarcomeric HCM whose efficacy has not been demonstrated in Danon disease. Myosin modulation in particular does not correct LAMP2 and should not be extrapolated without studies. Therapeutic specificity prevents morphological similarity from becoming a pharmacologic assumption and keeps surveillance, arrhythmias and transplantation as priorities.

Annual review verifies that weight, drug doses, device thresholds and contacts are up to date. Pathway maintenance prevents a rare progressive disease from being followed with obsolete protocols or intervals that are no longer proportionate.